Prolonged Low-Dose Paracetamol Trial for Ductal Closure in Preterm Neonates

A 2026 single-center, randomized, controlled, double-blind phase II pilot trial investigated intravenous paracetamol versus placebo for patent ductus arteriosus in extremely preterm infants. The dataset includes results from 39 infants, showing median ductal closure times of 3 days in the treatment group versus 14 days in the placebo group. It was authored by figshare admin karger and published under a CC-BY-4.0 license.

Use Cases

• Compare ductal closure rates based on treatment group assignment mentioned in the trial description.
• Analyze the relationship between paracetamol administration and adverse event profiles described in the results.
• Model the number needed to treat (NNT=3) for early paracetamol prophylaxis in extremely low gestational age infants.
• Assess the correlation between serum paracetamol levels and ductal closure outcomes as a secondary trial measure.

Strengths

• Data originates from a randomized, controlled, double-blind clinical trial, a gold-standard study design.
• Includes specific, reported primary and secondary outcomes such as median closure times (3 vs 14 days) and closure rates (75% vs 35%).
• Trial was registered with EudraCT and ClinicalTrials.gov, providing transparency and traceability.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is very small at 133.0 KB, indicating limited scope and sample size.

Provenance

Source

figshare

Collection Method

Single-center randomized controlled trial.

Time Range

Trial registration dates suggest data collection likely occurred around 2018-2020.

Freshness

Last updated 2026-05-14 05:55:44; freshness should be verified.